Through the 90-day period concluding February 19, 2026, Neurocrine Biosciences's top three insider stakeholders include Director Kevin Charles Gorman (551.29K shares), Chief Executive Officer Kyle Gano (150.81K shares), Director Gary A Lyons (120.48K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Kevin Charles Gorman | 551,293 | 17 Feb, 2026 | |
| Kyle Gano | Chief Executive Officer | 150,815 | 17 Feb, 2026 |
| Gary A Lyons | 120,482 | 04 Dec, 2025 | |
| Dimitri E. Grigoriadis | Chief Research Officer | 82,273 | 12 Oct, 2021 |
| Eric Benevich | Chief Commercial Officer | 63,190 | 17 Feb, 2026 |
| Darin Lippoldt | Chief Legal Officer | 54,729 | 17 Feb, 2026 |
| Matt Abernethy | Chief Financial Officer | 44,881 | 17 Feb, 2026 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 42,337 | 08 Feb, 2023 |
| William H Rastetter | 40,360 | 06 Nov, 2025 | |
| Eiry Roberts | Chief Medical Officer | 35,640 | 14 Feb, 2025 |
| Richard F Pops | 34,480 | 22 May, 2025 | |
| Julie Cooke | Chief Human Resources Officer | 34,170 | 17 Feb, 2026 |
| Jude Onyia | Chief Scientific Officer | 28,780 | 17 Feb, 2026 |
| Ingrid Delaet | Chief Regulatory Officer | 16,225 | 17 Feb, 2026 |
| Stephen A Sherwin | 12,542 | 03 Sep, 2025 | |
| David W. Boyer | Chief Corp. Affairs Officer | 11,581 | 17 Feb, 2026 |
| George J Morrow | 7,068 | 26 Nov, 2025 | |
| Leslie V Norwalk | 6,239 | 17 Dec, 2025 | |
| Johanna Mercier | 3,535 | 22 May, 2025 | |
| Shalini Sharp | 2,429 | 22 May, 2025 | |
| Christine A Poon | 1,435 | 22 May, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 13 Feb, 2026 | Kevin Charles Gorman | Common Stock | D | 34,380 | $124.12 | 551,293 | D | F |
| 13 Feb, 2026 | Kevin Charles Gorman | Common Stock | A | 5,377 | $0.00 | 524,850 | D | M |
| 13 Feb, 2026 | Kevin Charles Gorman | Common Stock | D | 2,901 | $124.12 | 521,949 | D | F |
| 13 Feb, 2026 | Kevin Charles Gorman | Common Stock | D | 3,024 | $124.12 | 519,473 | D | F |
| 13 Feb, 2026 | Kevin Charles Gorman | Common Stock | A | 5,604 | $0.00 | 522,497 | D | M |
| 13 Feb, 2026 | Kevin Charles Gorman | Common Stock | A | 63,724 | $0.00 | 585,673 | D | A |
| 13 Feb, 2026 | Darin Lippoldt | Common Stock | D | 365 | $0.00 | 54,729 | D | G |
| 13 Feb, 2026 | Darin Lippoldt | Common Stock | A | 2,083 | $0.00 | 51,628 | D | M |
| 13 Feb, 2026 | Darin Lippoldt | Common Stock | A | 2,017 | $0.00 | 50,634 | D | M |
| 13 Feb, 2026 | Darin Lippoldt | Common Stock | D | 1,124 | $124.12 | 50,504 | D | F |
| 13 Feb, 2026 | Darin Lippoldt | Common Stock | D | 1,089 | $124.12 | 49,545 | D | F |
| 13 Feb, 2026 | Darin Lippoldt | Common Stock | A | 9,968 | $0.00 | 60,472 | D | A |
| 13 Feb, 2026 | Darin Lippoldt | Common Stock | D | 5,378 | $124.12 | 55,094 | D | F |
| 13 Feb, 2026 | Kyle Gano | Common Stock | D | 1,385 | $124.12 | 146,225 | D | F |
| 13 Feb, 2026 | Kyle Gano | Common Stock | A | 2,241 | $0.00 | 146,254 | D | M |
| 13 Feb, 2026 | Kyle Gano | Common Stock | D | 1,210 | $124.12 | 145,044 | D | F |
| 13 Feb, 2026 | Kyle Gano | Common Stock | A | 2,566 | $0.00 | 147,610 | D | M |
| 13 Feb, 2026 | Kyle Gano | Common Stock | A | 9,968 | $0.00 | 156,193 | D | A |
| 13 Feb, 2026 | Kyle Gano | Common Stock | D | 5,378 | $124.12 | 150,815 | D | F |
| 13 Feb, 2026 | Eric Benevich | Common Stock | A | 16,613 | $0.00 | 72,153 | D | A |